Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 5, 1997, Pages 346-355

  Spino, Cathie ^a,e   Kahn, James O ^b   Dolin, Raphael ^c   Phair, John P ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Astra USA   (United States)

Author keywords

Advanced HIV disease; Prognostic factors; Survival

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; HEMOGLOBIN; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030689025     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199708150-00004     Document Type: Article

References (27)

1. Cameron DW, Heath-Chiozzi M, Dravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update [abstract #Mo.B.411]. Programs and Abstracts of the XIth International Conference on AIDS, Vancouver, Canada, July 1996.
2. Lalexari J, Haubrich R, Burger HU, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV), plus HIVID (zalcitabine, ddC) [abstract #LB.B.6033]. Programs and Abstracts of the XIth International Conference on AIDS, Vancouver, Canada, July 1996.
3. Coller AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
4. Massari R, Conant M, Mellors J, et al. A phase II open-label randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (ddI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients [abstract #200]. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, D.C., January 1996.
5. Markowitz M, Cao Y, Hurley A, et al. Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naive subjects chronically infected with HIV-1 [abstract #LB.B.6031]. Programs and Abstracts of the XIth International Conference on AIDS, Vancouver, Canada, July 1996.
6. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996;10(suppl 3):S1-11.
7. Sande MA, Carpenter CCJ, Cobbs CG, Holmes KK, Sanford JP. For the National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. Antiretroviral therapy for adult HIV-infected patients; recommendations from a state-of-the-art conference. JAMA 1993;270:2583-9.
8. Yarchoan R, Mitsuya H, Broder S. The immunology of HIV infection: implications for therapy. AIDS Res Hum Retroviruses 1992;8:1023-31.
9. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP, and the Multicenter AIDS Cohort Study. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994;7:287-95.
10. Yarchoan R, Venzon DJ, Pluda JM, et al. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991;115:184-9.
11. Apolonio KG, Hoover DR, He Y, et al. Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count < 50/microL. J Infect Dis 1995;171:829-36.
12. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley and Sons, 1981.
13. Randles RH, Wolfe DA. Introduction to the theory of nonparametric statistics. New York: John Wiley and Sons, 1979.
14. Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1984.
15. Stanley K. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
16. SAS Institute, Inc. SAS/STAT Software: The PHREG procedure, preliminary documentation. Carey, NC: SAS, 1991.
17. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991;338:265-9.
18. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts between 200 and 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
19. Derbyshire JH, Aboulker J. Didanosine for zidovudine-intolerant patients with HIV disease. Lancet 1992;340:1346-7.
20. Colford JM, Ngo L, Tager I. Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts. Am J Epidemiol 1994; 139:206-18.
21. Rothenberg R, Woelfel M, Stoneburner R, et al. Survival with the acquired immunodeficiency syndrome. N Engl J Med 1987;317: 1297-302.
22. Friedland GH. Survival differences in patients with AIDS. J Acquir Immune Defic Syndr 1991;4:144-53.
23. Carpenter CCJ, Mayer KH, Stein MD, Leibman BD, Fisher A, Fiore TC. Human immunodeficiency virus infection in North American women: experience with 200 cases and a review of the literature. Medicine 1991;70:307-25.
24. Lindan CP, Allen S, Serufilira AN, et al. Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 1992;116:320-8.
25. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:425-31.
26. Saag MS, Holodniy M, Kurtizkes DR, O'Brien WA, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-9.
27. Heath-Chiozzi M, Leonard J, Sun E. et al. Ritonavir clinical benefit correlates with HIV RNA and CD4 cell levels in advanced HIV illness [abstract #We.B.3127]. Programs and Abstracts of the XIth International Conference on AIDS, Vancouver, Canada, July 1996: